An evaluation of ovarian carcinoma-associated antigen defined by murine monoclonal antibody CF511 in sera from patients with ovarian carcinoma

K Ohkawa, K Takada, T Hatano, N Takizawa, Y Tsukada, K Yamada, Y Terashima, M Matsuda, K Machida
British journal of cancer · 1991 · doi:10.1038/bjc.1991.288 · PMID:1892754 · PMC1977496
other OA: gold public-domain-us
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Monoclonal antibody CF511 detects an elevated serum antigen in patients with ovarian carcinoma (especially advanced stages) and also in some with lung or breast carcinoma, correlating with disease progression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This study evaluated whether the murine monoclonal antibody CF511 antigen, a large glycoprotein detected by a competitive enzyme-linked immunosorbent assay, is elevated in human sera and can reflect disease status. Serum samples from 220 normal individuals and patients with various tumors and other diseases were tested; raised CF511 levels (≥18 U/mL) were absent in normals and were not found in several non-ovarian cancer groups, while elevated levels occurred in subsets of benign gynecological tumors (including endometriosis or ovarian cyst), breast cancer, and lung cancer. In ovarian carcinoma patients, the proportion with elevated CF511 increased with stage (42.3% stage I/II and 96.0% stage III/IV), and in patients with serial measurements, antigen levels correlated with clinical course before and after surgery. The paper’s explicit caveat is that elevated CF511 was detected in some benign gynecological conditions, limiting specificity. Relevance to endometriosis: the study reports raised CF511 levels in benign gynecological tumours “including endometriosis or ovarian cyst,” though its main focus is evaluating CF511 antigen as a marker across ovarian carcinoma, other cancers, and selected benign conditions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Murine monoclonal antibody CF511, raised against human ovarian clear cell carcinoma, detects a glycoprotein (Mr 600 kDa) called CF511 antigen which is elevated in the serum of many patients with ovarian carcinoma. A competitive enzyme-linked immunosorbent assay was developed to detect CF511 antigen in human serum and used to detected CF511 antigen in subjects with ovarian carcinoma and other diseases. No raised levels (less than 18 unit (U) ml-1) of the antigen were found in the serum of 220 normal individuals or of patients with germ cell tumours (n = 6), granulosa theca cell tumour (n = 1), gastric carcinomas (n = 10) and colo-rectal carcinomas (n = 8). Raised serum levels of CF511 antigen were found in 6/46 patients (13.0%) with benign gynaecological tumours (including endometriosis or ovarian cyst), in 5/7 patients (71.4%) with breast carcinoma and 16/21 (76.2%) lung carcinoma patients. In patients with ovarian carcinoma, 42.3% (11/26) of stage I and II, and 96.0% (24/25) of stage III and IV had levels of greater than or equal to 18 U ml-1. In all patients with serial determination of CF511 antigen levels before and after the surgery, the levels of antigen correlated with the clinical course of disease. Determination of CF511 antigen levels may be useful for detection of ovarian carcinoma as well as lung and breast carcinomas and for monitoring progress of disease and response to therapy.
Full text 2,239 characters · extracted from oa-doi-fallback · click to expand
Abstract Murine monoclonal antibody CF511, raised against human ovarian clear cell carcinoma, detects a glycoprotein (Mr 600 kDa) called CF511 antigen which is elevated in the serum of many patients with ovarian carcinoma. A competitive enzyme-linked immunosorbent assay was developed to detect CF511 antigen in human serum and used to detected CF511 antigen in subjects with ovarian carcinoma and other diseases. No raised levels (less than 18 unit (U) ml-1) of the antigen were found in the serum of 220 normal individuals or of patients with germ cell tumours (n = 6), granulosa theca cell tumour (n = 1), gastric carcinomas (n = 10) and colo-rectal carcinomas (n = 8). Raised serum levels of CF511 antigen were found in 6/46 patients (13.0%) with benign gynaecological tumours (including endometriosis or ovarian cyst), in 5/7 patients (71.4%) with breast carcinoma and 16/21 (76.2%) lung carcinoma patients. In patients with ovarian carcinoma, 42.3% (11/26) of stage I and II, and 96.0% (24/25) of stage III and IV had levels of greater than or equal to 18 U ml-1. In all patients with serial determination of CF511 antigen levels before and after the surgery, the levels of antigen correlated with the clinical course of disease. Determination of CF511 antigen levels may be useful for detection of ovarian carcinoma as well as lung and breast carcinomas and for monitoring progress of disease and response to therapy. This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 24 print issues and online access 251,40 € per year only 10,48 € per issue Buy this article - Purchase on SpringerLink - Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Author information Authors and Affiliations Rights and permissions About this article Cite this article Ohkawa, K., Takada, K., Hatano, T. et al. An evaluation of ovarian carcinoma-associated antigen defined by murine monoclonal antibody CF511 in sera from patients with ovarian carcinoma. Br J Cancer 64, 259–262 (1991). https://doi.org/10.1038/bjc.1991.288 Issue date: DOI: https://doi.org/10.1038/bjc.1991.288

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Antigens, Neoplasm Ovarian Neoplasms Antibodies, Monoclonal Antigens, Neoplasm Enzyme-Linked Immunosorbent Assay Female Genital Diseases, Female Genital Diseases, Female Humans Ovarian Neoplasms

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
pubmed
last seen: 2026-05-13T22:11:54.876058+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine